NCT03556813

Artificial Intelligence vs Physicians for Breast Cancer Patients' Information

Completed Last updated 25 April 2019

What this trial tests

trial testing survey in Breast Cancer in 150 participants. Completed in 20 January 2019.

Timeline

1 November 2018

Primary endpoint
1 December 2018

20 January 2019

Quick facts

Lead sponsor	Wefight
Status	Completed
Study type	OBSERVATIONAL
Enrollment	150
Start date	1 November 2018
Primary completion	1 December 2018
Estimated completion	20 January 2019
Sites	1 location across France

Drugs / interventions tested

• survey

Conditions studied

• Breast Cancer — all drugs for Breast Cancer →

Sponsor

Wefight

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Chatbots (contraction of "chat" and "robot") are a computer software program that use statistical learning and aim to simulate a conversation by text or voice message. The use of these chatbots was evaluated as part of the increase in therapeutic adherence and information on well-being and mental health.

In clinical studies, chatbots are useful in gathering information through questionnaires directly submitted during conversations or through keyword analyzes. There is no longer any delay between the moment the patient notices a side effect, for example, and the moment when the patient announces it during a consultation. The responses given by the chatbot do not constitute medical advice and only provide information on the treatments envisaged or in progress in the context of the management of breast cancer.

The main objective of the study is to show that the chatbot Vik's answers to the common questions asked by breast cancer patients about their therapeutic management are at least as satisfactory as answers given by a committee of multidisciplinary doctors

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

1. A Chatbot Versus Physicians to Provide Information for Patients With Breast Cancer: Blind, Randomized Controlled Noninferiority Trial.
   Bibault JE, Chaix B, Guillemassé A, Cousin S, et al · · 2019 · cited 112× · PMID 31774408 · DOI 10.2196/15787
2. Psychological distress during the COVID-19 pandemic in France: a national assessment of at-risk populations.
   Chaix B, Delamon G, Guillemassé A, Brouard B, et al · · 2020 · cited 51× · PMID 34192239 · DOI 10.1136/gpsych-2020-100349
3. Healthcare ex Machina: Are conversational agents ready for prime time in oncology?
   Bibault JE, Chaix B, Nectoux P, Pienkowsky A, et al · · 2019 · cited 47× · PMID 31008379 · DOI 10.1016/j.ctro.2019.04.002
4. Clinical Trials for Artificial Intelligence in Cancer Diagnosis: A Cross-Sectional Study of Registered Trials in ClinicalTrials.gov.
   Dong J, Geng Y, Lu D, Li B, et al · · 2020 · cited 25× · PMID 33042806 · DOI 10.3389/fonc.2020.01629
5. Characteristics of Artificial Intelligence Clinical Trials in the Field of Healthcare: A Cross-Sectional Study on ClinicalTrials.gov.
   Wang A, Xiu X, Liu S, Qian Q, et al · · 2022 · cited 12× · PMID 36294269 · DOI 10.3390/ijerph192013691
6. [New concepts of medical consultation in oncology].
   Bibault JE, Denis F, Guihard S, Clavier JB, et al · · 2020 · cited 6× · PMID 32753236 · DOI 10.1016/j.canrad.2020.05.001
7. Psychological Distress during the COVID-19 pandemic in France: a national assessment of at-risk populations
   Chaix B, Delamon G, Guillemasse A, Brouard B, et al · · 2020 · DOI 10.1101/2020.05.10.20093161